288 related articles for article (PubMed ID: 37498350)
21. History and current situation of neoadjuvant treatment for locally advanced esophageal cancer.
Li J; Ma S
Thorac Cancer; 2021 Sep; 12(17):2293-2299. PubMed ID: 34254738
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer.
Cleary JM; Mamon HJ; Szymonifka J; Bueno R; Choi N; Donahue DM; Fidias PM; Gaissert HA; Jaklitsch MT; Kulke MH; Lynch TP; Mentzer SJ; Meyerhardt JA; Swanson RS; Wain J; Fuchs CS; Enzinger PC
BMC Cancer; 2016 Jul; 16():468. PubMed ID: 27412386
[TBL] [Abstract][Full Text] [Related]
23. ERCC1 expression and tumor regression predict survival in esophageal squamous cell carcinoma patients receiving combined trimodality therapy.
Ge H; Lu Y; Chen Y; Zheng X; Wang W; Yu J
Pathol Res Pract; 2014 Oct; 210(10):656-61. PubMed ID: 25042384
[TBL] [Abstract][Full Text] [Related]
24. Clinical tools do not predict pathological complete response in patients with esophageal squamous cell cancer treated with definitive chemoradiotherapy.
Molena D; Sun HH; Badr AS; Mungo B; Sarkaria IS; Adusumilli PS; Bains MS; Rusch VW; Ilson DH; Rizk NP
Dis Esophagus; 2014; 27(4):355-9. PubMed ID: 24033404
[TBL] [Abstract][Full Text] [Related]
25. Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis.
Qin H; Liu F; Zhang Y; Liang Y; Mi Y; Yu F; Xu H; Li K; Lin C; Li L; Tian Z; Wang L
Front Immunol; 2023; 14():1108213. PubMed ID: 37033991
[TBL] [Abstract][Full Text] [Related]
26. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
[TBL] [Abstract][Full Text] [Related]
27. Effects of pre-operative enteral immunonutrition for esophageal cancer patients treated with neoadjuvant chemoradiotherapy: protocol for a multicenter randomized controlled trial (point trial, pre-operative immunonutrition therapy).
Cao Y; Han D; Yang S; Shi Y; Zhao S; Jin Q; Li J; Li C; Zhang Y; Shen W; He J; Wang M; Ji G; Li Z; He Y; Chen Q; Wei W; Chen C; Gong X; Wang J; Tan L; Wang H; Li H
BMC Cancer; 2022 Jun; 22(1):650. PubMed ID: 35698100
[TBL] [Abstract][Full Text] [Related]
28. New developments in the treatment of esophageal cancer.
Ilson DH
Clin Adv Hematol Oncol; 2004 Feb; 2(2):97-104. PubMed ID: 16163169
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of neoadjuvant immunotherapy combined with chemoradiotherapy or chemotherapy in esophageal cancer: A systematic review and meta-analysis.
Liu Y; Bao Y; Yang X; Sun S; Yuan M; Ma Z; Zhang W; Zhai Y; Wang Y; Men Y; Qin J; Xue L; Wang J; Hui Z
Front Immunol; 2023; 14():1117448. PubMed ID: 36761760
[TBL] [Abstract][Full Text] [Related]
30. The current status of neoadjuvant therapy for esophageal cancer.
Lin D; Leichman L
Semin Thorac Cardiovasc Surg; 2014; 26(2):102-9. PubMed ID: 25441001
[TBL] [Abstract][Full Text] [Related]
31. Prospective, open, multicentre Phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and cisplatin for esophageal carcinoma.
Ma HB; Di ZL; Wen J; Ke Y; Sun X; Ren J
Jpn J Clin Oncol; 2015 Feb; 45(2):169-75. PubMed ID: 25416813
[TBL] [Abstract][Full Text] [Related]
32. Diffusion-weighted MRI and
Xu X; Sun ZY; Wu HW; Zhang CP; Hu B; Rong L; Chen HY; Xie HY; Wang YM; Lin HP; Bai YR; Ye Q; Ma XM
Radiat Oncol; 2021 Jul; 16(1):132. PubMed ID: 34281566
[TBL] [Abstract][Full Text] [Related]
33. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
[TBL] [Abstract][Full Text] [Related]
34. Comparison of neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for esophageal cancer: a meta-analysis.
Jing SW; Qin JJ; Liu Q; Zhai C; Wu YJ; Cheng YJ; Czito BG; Wang J
Future Oncol; 2019 Jul; 15(20):2413-2422. PubMed ID: 31269806
[No Abstract] [Full Text] [Related]
35. Biomarkers for the prediction of esophageal cancer neoadjuvant chemoradiotherapy response: A systemic review.
Li Y; Liu J; Cai XW; Li HX; Cheng Y; Dong XH; Yu W; Fu XL
Crit Rev Oncol Hematol; 2021 Nov; 167():103466. PubMed ID: 34508841
[TBL] [Abstract][Full Text] [Related]
36. Total neoadjuvant therapy for locally advanced gastric cancer and esophagogastric junction adenocarcinoma: study protocol for a prospective, multicenter, single-arm, phase II clinical trial.
Shi J; Li N; Tang Y; Jiang L; Yang L; Wang S; Song Y; Liu Y; Fang H; Lu N; Qi S; Chen B; Li Z; Liu S; Wang J; Wang W; Zhu S; Yang J; Li Y; Zhao D; Jin J
BMC Gastroenterol; 2022 Jul; 22(1):359. PubMed ID: 35902798
[TBL] [Abstract][Full Text] [Related]
37. Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: The NEOCRTEC5010 Randomized Clinical Trial.
Yang H; Liu H; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Han Y; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Yang H; Li T; Zhang X; Li Q; Wang G; Chen B; Mao T; Kong M; Guo X; Lin T; Liu M; Fu J
JAMA Surg; 2021 Aug; 156(8):721-729. PubMed ID: 34160577
[TBL] [Abstract][Full Text] [Related]
38. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
[No Abstract] [Full Text] [Related]
39. Optimal timing for prediction of pathologic complete response to neoadjuvant chemoradiotherapy with diffusion-weighted MRI in patients with esophageal cancer.
Borggreve AS; Heethuis SE; Boekhoff MR; Goense L; van Rossum PSN; Brosens LAA; van Lier ALHMW; van Hillegersberg R; Lagendijk JJW; Mook S; Ruurda JP; Meijer GJ
Eur Radiol; 2020 Apr; 30(4):1896-1907. PubMed ID: 31822974
[TBL] [Abstract][Full Text] [Related]
40. Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial.
Eyck BM; van Lanschot JJB; Hulshof MCCM; van der Wilk BJ; Shapiro J; van Hagen P; van Berge Henegouwen MI; Wijnhoven BPL; van Laarhoven HWM; Nieuwenhuijzen GAP; Hospers GAP; Bonenkamp JJ; Cuesta MA; Blaisse RJB; Busch OR; Creemers GM; Punt CJA; Plukker JTM; Verheul HMW; Spillenaar Bilgen EJ; van der Sangen MJC; Rozema T; Ten Kate FJW; Beukema JC; Piet AHM; van Rij CM; Reinders JG; Tilanus HW; Steyerberg EW; van der Gaast A;
J Clin Oncol; 2021 Jun; 39(18):1995-2004. PubMed ID: 33891478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
